Recent News

• 03.20.2025 - ARS Pharmaceuticals 4Q 2024 Financial Results Conference Call
• 03.10.2025 - Leerink Partners Global Healthcare Conference
• 03.07.2025 - Louise Chen
• 03.05.2025 - ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
• 03.03.2025 - ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
• 02.21.2025 - ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
• 02.18.2025 - ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
• 02.13.2025 - Andreas Argyrides
• 02.12.2025 - Oppenheimer 35th Annual Healthcare Conference
• 02.05.2025 - ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

Recent Filings

• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 144 Report of proposed sale of securities
• 03.05.2025 - 8-K Current report
• 02.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2025 - 144 Report of proposed sale of securities
• 01.31.2025 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 01.13.2025 - 8-K Current report